These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16829073

  • 1. Arylamine based cathepsin K inhibitors: investigating P3 heterocyclic substituents.
    Shinozuka T, Shimada K, Matsui S, Yamane T, Ama M, Fukuda T, Taki M, Takeda Y, Otsuka E, Yamato M, Naito S.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6807-19. PubMed ID: 16829073
    [Abstract] [Full Text] [Related]

  • 2. Potent and selective cathepsin K inhibitors.
    Shinozuka T, Shimada K, Matsui S, Yamane T, Ama M, Fukuda T, Taki M, Takeda Y, Otsuka E, Yamato M, Mochizuki S, Ohhata K, Naito S.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6789-806. PubMed ID: 16842999
    [Abstract] [Full Text] [Related]

  • 3. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.
    Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL.
    Bioorg Med Chem Lett; 2005 Sep 01; 15(17):3891-5. PubMed ID: 15993587
    [Abstract] [Full Text] [Related]

  • 4. New chemotypes for cathepsin K inhibitors.
    Teno N, Irie O, Miyake T, Gohda K, Horiuchi M, Tada S, Nonomura K, Kometani M, Iwasaki G, Betschart C.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2599-603. PubMed ID: 18375120
    [Abstract] [Full Text] [Related]

  • 5. Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K.
    Fenwick AE, Garnier B, Gribble AD, Ife RJ, Rawlings AD, Witherington J.
    Bioorg Med Chem Lett; 2001 Jan 22; 11(2):195-8. PubMed ID: 11206457
    [Abstract] [Full Text] [Related]

  • 6. Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K.
    Fenwick AE, Gribble AD, Ife RJ, Stevens N, Witherington J.
    Bioorg Med Chem Lett; 2001 Jan 22; 11(2):199-202. PubMed ID: 11206458
    [Abstract] [Full Text] [Related]

  • 7. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.
    Altmann E, Green J, Tintelnot-Blomley M.
    Bioorg Med Chem Lett; 2003 Jun 16; 13(12):1997-2001. PubMed ID: 12781182
    [Abstract] [Full Text] [Related]

  • 8. Discovery of selective and nonpeptidic cathepsin S inhibitors.
    Irie O, Ehara T, Iwasaki A, Yokokawa F, Sakaki J, Hirao H, Kanazawa T, Teno N, Horiuchi M, Umemura I, Gunji H, Masuya K, Hitomi Y, Iwasaki G, Nonomura K, Tanabe K, Fukaya H, Kosaka T, Snell CR, Hallett A.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):3959-62. PubMed ID: 18572405
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and stepwise optimization of nitrile-based inhibitors of cathepsins B and L.
    Cianni L, Rocho FDR, Bonatto V, Martins FCP, Lameira J, Leitão A, Montanari CA, Shamim A.
    Bioorg Med Chem; 2021 Jan 01; 29():115827. PubMed ID: 33254069
    [Abstract] [Full Text] [Related]

  • 10. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
    Robichaud J, Oballa R, Prasit P, Falgueyret JP, Percival MD, Wesolowski G, Rodan SB, Kimmel D, Johnson C, Bryant C, Venkatraman S, Setti E, Mendonca R, Palmer JT.
    J Med Chem; 2003 Aug 14; 46(17):3709-27. PubMed ID: 12904076
    [Abstract] [Full Text] [Related]

  • 11. Acyclic cyanamide-based inhibitors of cathepsin K.
    Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Willard DH, Wright LL.
    Bioorg Med Chem Lett; 2005 Jun 15; 15(12):3039-43. PubMed ID: 15896958
    [Abstract] [Full Text] [Related]

  • 12. Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B.
    Lynas JF, Hawthorne SJ, Walker B.
    Bioorg Med Chem Lett; 2000 Aug 07; 10(15):1771-3. PubMed ID: 10937745
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
    Tully DC, Liu H, Alper PB, Chatterjee AK, Epple R, Roberts MJ, Williams JA, Nguyen KT, Woodmansee DH, Tumanut C, Li J, Spraggon G, Chang J, Tuntland T, Harris JL, Karanewsky DS.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1975-80. PubMed ID: 16446091
    [Abstract] [Full Text] [Related]

  • 14. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
    Wu Z, Yang C, Graham TH, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Shen Z, Chen Q, Bleasby K, Sinharoy R, Hale JJ, Tata JR, Pinto S, Colletti SL, Shen DM.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1727-30. PubMed ID: 22290078
    [Abstract] [Full Text] [Related]

  • 15. Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.
    Setti EL, Venkatraman S, Palmer JT, Xie X, Cheung H, Yu W, Wesolowski G, Robichaud J.
    Bioorg Med Chem Lett; 2006 Aug 15; 16(16):4296-9. PubMed ID: 16750630
    [Abstract] [Full Text] [Related]

  • 16. Dipeptide nitrile inhibitors of cathepsin K.
    Altmann E, Aichholz R, Betschart C, Buhl T, Green J, Lattmann R, Missbach M.
    Bioorg Med Chem Lett; 2006 May 01; 16(9):2549-54. PubMed ID: 16480867
    [Abstract] [Full Text] [Related]

  • 17. Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design.
    Ménard R, Therrien C, Lachance P, Sulea T, Qo H, Alvarez-Hernandez AD, Roush WR.
    Biol Chem; 2001 May 01; 382(5):839-45. PubMed ID: 11517939
    [Abstract] [Full Text] [Related]

  • 18. 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors.
    Zhou NE, Guo D, Thomas G, Reddy AV, Kaleta J, Purisima E, Menard R, Micetich RG, Singh R.
    Bioorg Med Chem Lett; 2003 Jan 06; 13(1):139-41. PubMed ID: 12467634
    [Abstract] [Full Text] [Related]

  • 19. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
    Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Wells-Knecht KJ, Wright LL.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2209-13. PubMed ID: 15837295
    [Abstract] [Full Text] [Related]

  • 20. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
    Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Massé F, Riendeau D, Toulmond S, Percival MD.
    J Med Chem; 2005 Dec 01; 48(24):7535-43. PubMed ID: 16302795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.